objectives To describe and correlate placental characteristics from pregnancies in HIV-infected and HIV-negative women with maternal and infant clinical and immunological data.
Introduction
Improved strategies to prevent mother-to-child transmission of HIV have substantially reduced vertical transmission of HIV and HIV-associated maternal deaths [1] . With the widespread adoption of WHO's option B+ recommendation, South African HIV-infected women now initiate lifelong antiretroviral therapy (ART) from antenatal diagnosis, resulting in prolonged foetal ART exposure, that in subsequent pregnancies may precede conception. There is growing evidence of associations between ART during pregnancy and adverse maternal and foetal outcomes [2] [3] [4] [5] . Critically, however, mechanistic biological data on the effects of HIV and ART during pregnancy are lacking. It is plausible that HIV and ART could influence placentation and placental development during pregnancy.
Successful placental implantation is an immunemediated process involving a dynamic and finely tuned balance of immune and angiogenic systems [6] . Placental trophoblast cells invade the uterine spiral arterioles causing vascular remodelling and the low-pressure placental vasculature required for successful pregnancy. The maternal immune system, although recognising the paternal antigens in foetal tissues, remains tolerant, allowing pregnancy to continue. Disruption to these immune-mediated processes can impair placentation and lead to pregnancyspecific disease and adverse outcomes such as pregnancyinduced hypertensive disorders and recurrent early pregnancy loss [7] [8] [9] .
Investigations of placental pathology in HIV infection are limited to the placenta's role in vertical transmission, and reports on the pathology are conflicting [10] [11] [12] [13] [14] . Most reports fail to identify specific lesions associated with HIV, and direct infection of the placenta is not a requirement for vertical transmission; nor does the presence of virus in placental tissue guarantee foetal infection [11, 12, [15] [16] [17] . Lesions of the chorionic villi noted in the placentas of HIV-infected women are thought to be immune-mediated [16, 18, 19] . In addition, ART can alter the local and systemic immunological milieu. In such a fundamental system, any imbalance has implications for the foetus beyond the vertical transmission of HIV and passive transfer of maternal antibodies. Pregnant women on ART may be at increased risk of hepatotoxicity and hypertensive placental insufficiency [2] [3] [4] . Pre-eclampsia and other pregnancy-induced hypertensive disorders arise from immune-mediated disruption of placentation; it is possible that the immune dysregulation of HIV and ART may underlie or influence such pathology. Mechanistic data to elucidate these observations are required.
Here, we describe the histopathological features of the placentas from uncomplicated pregnancies in HIVinfected and uninfected women and explore possible associations with baseline characteristics in a low socioeconomic urban setting.
Methods
We conducted a prospective descriptive study of the macroscopic and histological features of placentas from a cohort of HIV-infected and HIV-negative women who presented for delivery at the Kraaifontein Midwife Obstetric Unit (MOU) in Cape Town, South Africa.
Participants
The sample was identified from the Mother Infant Health Study (MIHS) cohort enrolled between July 2012 and June 2013. All data, apart from those pertaining to the placenta, were collected in the parent study using standardised study forms. The MIHS was a prospective cohort study with the primary objective of determining the incidence of infectious morbidity (any infection) in HIV-exposed uninfected (HEU) and HIV-unexposed (HU) infants [20] . In the MIHS, HIV-infected mothers and their HIV-exposed infants and HIV-negative/HU controls were recruited post-natally from the labour ward at Kraaifontein MOU, a midwife-managed facility for uncomplicated vaginal deliveries. Women with antenatal or peri-partum complications were referred to hospital and not eligible. The MOU serves a population of 218 000 and manages over 2000 deliveries per year, half of which are referred. The population is predominantly black or of mixed ancestry in a low-income urban area with 21% unemployment. Over 85% of housing is formal with amenities [21] . During the study period, the HIV prevalence at delivery at the MOU was 26.2% [22] .
Recruitment for the MIHS specified uncomplicated deliveries and was restricted to mothers from four welldefined low socio-economic neighbourhoods. Women with complicated or high-risk pregnancies were referred for hospital management antenatally (e.g. maternal medical conditions such hypertensive disorders, diabetes, autoimmune disease; and other obstetric complications including history of recurrent pregnancy loss, severe growth restriction identified antenatally and multiple pregnancy.) These women did not deliver at the MOU and were not eligible for inclusion. Women with no antenatal care or who delivered before arrival at the MOU, those requiring emergency care or with premature labour were also excluded. Infants were excluded if their birth gestation was less than 34 completed weeks, their weight <2000 g, or if they required emergency care at birth. HIV-infected and uninfected women were frequencymatched 1:1 for race-ethnicity and date of delivery within a 30 day period.
At enrolment, a research nurse conducted an interview and abstracted data from the maternal obstetric record using standardised study report forms. Information included maternal obstetric and medical history and HIV treatment history and antenatal CD4 count in HIVinfected women. Data on smoking, alcohol and recreational drug use were collected at interview at the scheduled 2-week post-natal visit and were therefore missing from those participants who were lost to the parent study at this point. Maternal weight was measured by standardised techniques at this time point. Based on data retrieved at delivery, there were no differences between those women who did not return at 2 weeks and those who did: missing substance use data were likely to be missing at random [22] .
Maternal blood samples were drawn at enrolment (i.e. within 8 h of delivery) for CD4 count (all subjects) and viral load (HIV-infected women only). The National Health Laboratory Services performed the assays at the Tygerberg Hospital laboratory according to standardised protocols. Infant birthweight, length and head circumference were abstracted from the infant Road to Health Booklet (RTHB) at enrolment. The RTHB is a caregiver held record of infant birth, growth, immunisations and other medical treatment. Birth anthropometry is recorded in the booklet by the attending midwife at the MOU.
During the study, the ART strategy for the Prevention of Mother-to-Child Transmission of HIV (PMTCT) in the Western Cape was determined by maternal CD4 count (WHO Option A) [23] . Women with a CD4 count >350 cells/ml received daily zidovudine (AZT) during pregnancy and a single dose of nevirapine (NVP) during labour. Those with a CD4 count <350 cells/ll commenced triple ART comprising tenofovir disoproxil fumarate, lamivudine/emtricitabine and NVP [24] .
Placenta processing
Placentas were collected after birth by the clinical staff and refrigerated at 4°C until placed in 10% buffered formalin within 24 h of delivery. All examinations and processes were performed according to the standard operating procedures of the Department of Pathology at Stellenbosch University and Tygerberg Hospital. After weighing and macroscopic examination, four representative portions were trimmed and paraffin-embedded according to laboratory protocols. A standard procedure was used for the cut-up: the cord and membrane block comprised a membrane roll, one section of cord from the foetal end and one from the placental end; the three parenchymal sections included one section from any visible abnormal area if present, and two from macroscopically normal tissue. Tissue sections (3-5 lm) were cut and stained with haemotoxylin and eosin for histological examination by two expert placental pathologists blinded to maternal HIV status. A third placental pathologist examined 10% of the slides to ensure consistency and accuracy. Results were reported according to a standard template and macroscopic and microscopic features combined to report cluster diagnoses [25] .
Statistical analysis
Data were analysed using STATA version 12 (StataCorp LP, College Station, Texas, USA). Significance was tested using a two-sample t-test or Wilcoxon rank-sum test depending on the distribution for numerical data and the v 2 test or Fisher's exact test for categorical data. Logistic regression was used to evaluate the associations between maternal HIV infection and treatment, and placental findings. Multivariate models were fitted including known or suspected risk factors for the primary outcomes. Many of these clinical risk factors and outcomes associated with the placental lesions were excluded by study design, that is hypertensive disorders of pregnancy, diabetes mellitus and autoimmune disease; multiple pregnancy, infant prematurity, severe growth restriction and acute birth complications. Maternal age was included in all models. Smoking, maternal weight and parity, variables which can affect placental weight, were included when low placental weight was the outcome. Parity was included for those lesions that can recur in subsequent pregnancies (e.g. villitis of unknown aetiology (VUE); foetal thrombotic vasculopathy in some instances); and parity and CD4 count for those lesions with presumed immune-mediated pathophysiology [maternal vascular malperfusion (MVM) and VUE [26] ].
As the study was nested within a larger project, power considerations could not be included in the design. Therefore, this study should be considered exploratory.
The MIHS and placental substudy were approved by the Human Research Ethics Committee at Stellenbosch University (South Africa) and the Research Ethics Board at the University of British Columbia (Canada). Specific informed consent was requested for collection and examination of the placenta.
Results
From 264 mother-infant pairs enrolled in the MIHS, 223 (84%) placentas were available, 120 (54%) from HIVinfected women. The main reason for non-inclusion was unclear or absent labelling of placentas by the midwives immediately after delivery where it was not possible to allocate a specimen to a particular patient. More placentas being excluded from HIV-negative women, otherwise there were no significant differences between women for whom the placenta was available and those for whom it was not (Table S1) .
A total of 120 women were HIV infected (54%) and were slightly older than women in the HIV-negative group (median 27. There were no differences in gestational age at first antenatal visit or delivery, or the sex of the infant. Despite the restriction of the sample to uncomplicated pregnancies, the infants of HIV-infected women had a slightly lower mean birthweight (mean 3115 g [95% (Tables 1  and 2) .
Placental weight and histological cluster diagnoses were categorised by HIV status and by PMTCT treatment status in HIV-infected women (Table 2) . Half the samples were below the 10th percentile expected weight for gestation compared to standard tables for singleton placental weights [27] , but the proportion did not differ significantly according to HIV status or PMTCT received (mean placental weight for total sample 421.5 g [95% confidence interval 411.02-431.8]; reference standard mean weight at 39 weeks' gestation 519 g). This did not change after adjusting for confounding ( Table 3) .
The proportion of samples meeting the criteria for a cluster diagnosis was similar in the HIV-infected and HIV-negative women (39.2% vs. 44.7%).
Chronic villitis of unknown aetiology was less common in HIV-infected women (9.2% vs. 18.5%; P = 0.04), but the relationship did not persist after adjustment for smoking, CD4 count and parity (adjusted odds ratio [OR] 0.45 [95% confidence interval 0.19-1.06]; Table 3 ).
Maternal vascular malperfusion (MVM) was more frequent in the HIV-infected group (24.2% vs. 12.6%; P = 0.03). HIV infection increased the odds of MVM 2.21 fold, which increased after adjustment for smoking, CD4 count and parity (adjusted OR 2.90 [95% confidence interval 1.11-7.57]; Table 3 ). When PMTCT was included as a variable in the HIV-infected group, receipt of ART increased the odds for MVM but was not statistically significant (aOR 1.71 [95% confidence interval 0.57-5.14]). Otherwise the frequency of the individual pathological cluster diagnoses did not differ significantly between the groups (Table 2) .
No specific lesions were associated with placentas that weighed less than the 10th percentile expected weight for gestation (data not shown). Placental weight was significantly correlated with birthweight in both HIV-exposed and HIV-unexposed pregnancies (r = 0.55; P < 0.001 HIV exposed and r = 0.43; P < 0.001 HIV unexposed; r = 0.51; P < 0.001 total). On multivariate analysis, multiparity (i.e. the index pregnancy being a second or subsequent pregnancy) was strongly and significantly associated with having a placenta weighing less than the 10th percentile expected weight for gestation. When the analysis was restricted to primigravida women only, no other associations became apparent (Table 3) .
Discussion
We present, to our knowledge, the largest analysis of placentas from a well-matched group of HIV-infected and HIV-negative women experiencing uncomplicated vaginal deliveries at term in a resource-limited setting [10] [11] [12] [13] [14] [15] [16] [17] . This limits much of the confounding owing to gestational age and obstetric complications seen in hospital-based populations in other studies [10, 13, 14, 16, 17, 19] , allowing us to generalise to similar healthy populations. Moreover, HIV-infected and HIV-negative women were from the same communities and similar in their socioeconomic, behavioural and cultural characteristics, thus further limiting unmeasured confounders. Our key finding was that HIV-infected women were more likely to have MVM than HIV-negative women; in this small sample, no significant association by PMTCT treatment was apparent. Otherwise the groups were similar in terms of placental characteristics.
We did not see significant differences in placental weight by HIV status. Interestingly, half the placentas in both groups weighed less than the 10th percentile expected weight for gestational age. This lower placental weight was not significantly correlated with maternal weight at 2 weeks post-partum in either group.
Placental weight was weakly correlated with birthweight. While mean birthweight was lower in HIVexposed infants, this was not true of the mean placental weight. The presence of placental pathology did not explain increased prevalence of low placental weight, and no single diagnosis was associated with placental weight less than the 10th percentile expected weight for gestation. A small placenta was associated with MVM but this is expected, as a small placenta is a diagnostic criterion for this condition. Given that enrolment was restricted to uncomplicated pregnancies, these observations of low placental weight occurred in a cohort with normal and near-normal birthweights. A previous small sample from Toronto (n = 26) found that placental weight was lower in HIV-infected women than in controls [28] ; in contrast, in our study, the proportions of small placentas were similar between groups, and not influenced by smoking, maternal CD4 count and maternal weight. This would indicate that HIV is not the cause and that other mechanisms require consideration. It is possible that unmeasured factors accounted for the large proportion of small placentas, for example socio-economic or nutritional factors common in the population. Alternatively, the standard reference tables may be inappropriate for South Africa. These reference values were derived from the USA [27] , and there may be nutritional or other lifestyle factors that differ in the South African population.
Regarding placental cluster diagnoses, MVM occurred in greater proportions in the HIV-infected group. MVM is diagnosed by a constellation of histopathological findings (Table 2 ) and is strongly associated with hypertensive disorders of pregnancy, maternal smoking and recreational drug use, long-standing maternal diabetes and thrombophilia [26] . The women in this sample were not hypertensive or diabetic (exclusion criteria), and the prevalence of substance use was low. These lesions were therefore subclinical and not associated with maternal hypertension or adverse birth outcomes.
Features of MVM consistent with the changes in chronic hypertension have been described in stillbirths from HIV-infected women on ART in Botswana. MVM The macroscopic and microscopic criteria for Cluster Diagnoses are as follows [25] . Histological review predated the publications of the revised placental classification in 2015 [26] . Placental abruption: Macroscopic >15% adherent retroplacental haematoma; Microscopic (minimum 2 criteria):Retroplacental haemorrhage, overlying infarction, intravillous haemorrhage. Maternal Vascular Malperfusion (minimum 3 criteria): small placenta (<10th percentile weight for gestation), extensive microscopic infarction (>20% at term), accelerated maturation, distal villous hypoplasia, decidual vasculopathy, increased syncytial knots, increased perivillous fibrin, increased extravillous trophoblasts. Foetal thrombotic vasculopathy (minimum 2 criteria): cord thrombosis, chorionic plate/stem villous thrombosis, avascular villi, villous-stromal karyorrhexis. MVM-Maternal Vascular Malperfusion; VUE -Villitis of Unknown Etiology. *Includes 2 women for whom no PMTCT is documented. †Expressed as a percentage of the HIV-infected women.
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prevalence was similar to that in the HIV-negative cohort but differed from an HIV-infected group not on ART (i.e. untreated HIV or receiving AZT monotherapy). Of note, more than 25% of the women with this lesion had no evidence of documented hypertension during pregnancy [29] . There is conflicting evidence regarding the relationship between pregnancy-induced hypertensive disorders (including pre-eclampsia and eclampsia) and ART; a recent systematic review could not draw conclusions due to high risk of bias [30] . It is possible that disruption of placentation secondary to immune restoration following ART predisposes to MVM which could cause pregnancy-associated hypertension. Some of these changes may be specific to certain antiretrovirals: the OCTANE study in healthy non-pregnant women found that NVPcontaining regimens were associated with raised systolic and diastolic blood pressure [31] and findings from the recently published PROMISE study suggest that different ART regimens in pregnancy are associated with different maternal adverse events and adverse pregnancy outcomes [32] . The women we describe were receiving NVP-based ART. In our sample, there was no difference in the prevalence of MVM between women on ART vs. AZT, nor did duration of treatment influence the outcome. The aOR of MVM was 1.17 times greater in the women receiving ART but this was not statistically significant. The association between maternal smoking and MVM has been demonstrated [33] . Adjustment for smoking increased the association with HIV infection and MVM in multivariate analysis. However, smoking data were incomplete, so we could not draw definitive conclusions.
VUE is an inflammatory lesion of the placenta characterised by a lymphohistiocytic infiltrate affecting varying proportions of the villous tree in the absence clinical, microbiological or serological evidence of infection in the mother or infant. It occurs in 5-15% of term pregnancies and while the infant is usually unaffected, may contribute to intra-uterine growth restriction and foetal loss [34] . The infiltrate is characterised by CD8+ T cells and activated CD68+ macrophages. Chromogenic in situ hybridisation of the placentas of male infants shows the CD8+ T cells to be of maternal origin (female) and the macrophages to be foetal (male) [35, 36] . As such, VUE is caused by maternal lymphocytes in the foetal villous tissue. A study from India found low levels of VUE in HIV-infected women, ascribed to maternal immune compromise. However, results were not correlated with CD4 count [12] . A Cape Town hospital-based study including stillbirths found an increased prevalence of the lesion in women with low CD4 counts [19] but preceded the more effective PMTCT strategies in place during our study. Baurakiades et al., commenting on the increased numbers of CD8+ T cells observed in the placenta of HIV-infected women, postulated the presence of an HIV-specific villitis, distinct from VUE [16] . We also described a lower odds of VUE in HIV-infected women which was unaffected by CD4 count or parity. Future work will attempt to characterise the immune infiltrate in these samples. This study draws on a large well-matched sample of uncomplicated midwife-managed deliveries and so has the advantage of reducing the confounding effect of gestation and foetal and/or maternal complications necessitating hospital admission. Specimens from hospital-based deliveries include an expanded range of gestational ages and those associated with maternal and/or foetal complications, including pregnancy loss. Many of these adverse outcomes could have a placental aetiology. The disadvantage of such restriction is that any changes in putative placental causes of obstetric complications (which may be associated with HIV and ART) are excluded. This represents a descriptive analysis of placental lesions by HIV and PMTCT status; as the participants were well, any pathological findings were considered subclinical.
Being nested within a larger project, the study was neither powered to assess the differences in placental lesions, nor to account for the potential effects of different PMTCT treatments, which are subjects of interest. As such, we were limited to an exploratory role.
The low number of participants with smoking, alcohol and substance use data -all potential confounders in placental pathology -has limited the analysis although the proportions are low. As discussed in the Methods section, this was determined to be missing at random. When the smoking variable was removed from the models, the effect on the association between HIV and the outcome was unchanged (data not shown).
Conclusions
Our findings are notable for the limited differences observed at the placental level between the HIV-infected and uninfected women without adverse birth outcomes. This may reflect the success of the PMTCT programme in this area of Cape Town, in that treated HIV infection in uncomplicated pregnancies presents similar placental and foetal outcomes to HIV unaffected pregnancies. Also of note are the low placental weights, regardless of HIV status, in comparison with international reference standards; use of these reference standards may not be appropriate in our population.
It is possible that placental pathology (such as MVM) may underlie the development of hypertensive disorders of pregnancy observed in some HIV-infected women on ART and that these lesions, while more common, remained subclinical in this cohort. Larger studies are required to investigate this hypothesis which may have programmatic implications given the increasing number of HIV-infected women who start ART before or in early pregnancy and the potential clinical significance of hypertensive disorders of pregnancy.
